Evidence map›Paper›PMID 30814737›Full record

ArticleNature2019

An integrative systems genetic analysis of mammalian lipid metabolism.

Benjamin L Parker, Anna C Calkin, Marcus M Seldin, Michael F Keating, Elizabeth J Tarling, Pengyi Yang, Sarah C Moody, Yingying Liu, Eser J Zerenturk, Elise J Needham and 17 more

Abstract read
In one paragraph

Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Metabolites · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. ACAD10 and ACAD11 allow entry of 4-hydroxy fatty acids into β-oxidation.Cellular and molecular life sciences : CMLS · 2024
    Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Benjamin L ParkerMetabolic Systems Biology Laboratory, Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Sydney, New South Wales, Australia.
Anna C CalkinLipid Metabolism & Cardiometabolic Disease Laboratory, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia. anna.calkin@baker.edu.au.
Marcus M SeldinDepartment of Human Genetics/Medicine, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Michael F KeatingLipid Metabolism & Cardiometabolic Disease Laboratory, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
Elizabeth J TarlingDepartment of Medicine, Division of Cardiology, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Pengyi YangCharles Perkins Centre, School of Mathematics and Statistics, University of Sydney, Sydney, New South Wales, Australia.
Sarah C MoodyLipid Metabolism & Cardiometabolic Disease Laboratory, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
Yingying LiuLipid Metabolism & Cardiometabolic Disease Laboratory, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
Eser J ZerenturkLipid Metabolism & Cardiometabolic Disease Laboratory, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
Elise J NeedhamMetabolic Systems Biology Laboratory, Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Sydney, New South Wales, Australia.
Matthew L MillerMolecular Biology Institute, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Bethan L CliffordDepartment of Medicine, Division of Cardiology, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Pauline MorandDepartment of Biological Chemistry, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Matthew J WattDepartment of Physiology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.
Ruth C R MeexDepartment of Physiology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.
Kang-Yu PengMetabolomics Laboratory, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
Richard LeeIonis Therapeutics Inc., Carlsbad, CA, USA.
Kaushala JayawardanaMetabolomics Laboratory, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
Calvin PanDepartment of Human Genetics/Medicine, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Natalie A MellettMetabolomics Laboratory, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
Jacquelyn M WeirMetabolomics Laboratory, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
Ross LazarusMetabolomics Laboratory, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
Aldons J LusisDepartment of Human Genetics/Medicine, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Peter J MeikleMetabolomics Laboratory, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
David E JamesMetabolic Systems Biology Laboratory, Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Sydney, New South Wales, Australia.
Thomas Q de Aguiar VallimDepartment of Medicine, Division of Cardiology, University of California Los Angeles (UCLA), Los Angeles, CA, USA. tvallim@mednet.ucla.edu.
Brian G DrewCentral Clinical School, Department of Medicine, Monash University, Melbourne, Victoria, Australia. brian.drew@baker.edu.au.

Funding

Systems genomics of metabolic syndrome traitsP01HL028481 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LUSIS, ALDONS JAKE · 1985 to 2019
$50.2M
Novel FXR-dependent Molecular Mechanisms in the Regulation of Liver MetabolismR01DK118064 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EDWARDS, PETER A, VALLIM, THOMAS A · 2019 to 2022
$2.1M
Post-Translational Regulation of Lipid MetabolismR01HL136543 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TARLING, ELIZABETH JOANNA · 2017 to 2021
$1.9M
Transcriptional control of microRNAs in lipid metabolism and atherosclerosisR01HL122677 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VALLIM, THOMAS A · 2016 to 2020
$1.9M
Novel Post-Transcriptional Regulators of Lipid MetabolismR01DK112119 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VALLIM, THOMAS A · 2017 to 2020
$1.7M
Novel transcriptional regulators of bile acid metabolism and hepatotoxicityR01DK102559 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EDWARDS, PETER A · 2014 to 2017
$1.3M
Role of ABCG1 in lipid homeostasis, inflammation and innate immunityR00HL118161 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TARLING, ELIZABETH JOANNA · 2015 to 2017
$740k
Role of ABCG1 in lipid homeostasis, inflammation and innate immunityK99HL118161 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TARLING, ELIZABETH JOANNA · 2013 to 2014
$181k
NHLBI NIH HHS K99 HL118161NHLBI NIH HHS P01 HL028481NHLBI NIH HHS R00 HL118161NHLBI NIH HHS R01 HL122677NHLBI NIH HHS R01 HL136543NIDDK NIH HHS R01 DK102559NIDDK NIH HHS R01 DK112119NIDDK NIH HHS R01 DK118064
6 · The paper itself

Abstract

Dysregulation of lipid homeostasis is a precipitating event in the pathogenesis and progression of hepatosteatosis and metabolic syndrome. These conditions are highly prevalent in developed societies and currently have limited options for diagnostic and therapeutic intervention. Here, using a proteomic and lipidomic-wide systems genetic approach, we interrogated lipid regulatory networks in 107 genetically distinct mouse strains to reveal key insights into the control and network structure of mammalian lipid metabolism. These include the identification of plasma lipid signatures that predict pathological lipid abundance in the liver of mice and humans, defining subcellular localization and functionality of lipid-related proteins, and revealing functional protein and genetic variants that are predicted to modulate lipid abundance. Trans-omic analyses using these datasets facilitated the identification and validation of PSMD9 as a previously unknown lipid regulatory protein. Collectively, our study serves as a rich resource for probing mammalian lipid metabolism and provides opportunities for the discovery of therapeutic agents and biomarkers in the setting of hepatic lipotoxicity.

Indexed as

ProteomicsAnimalsHEK293 CellsHumansLipid MetabolismLipidsLiverMaleMiceMice, Inbred C57BLMice, Inbred DBAObesityProteasome Endopeptidase ComplexLipidsProteasome Endopeptidase ComplexPsmd9 protein, mouse

Identifiers

PMID30814737
PMCPMC6656374

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.